A Phase 1 clinical study published in Cancer Cell highlights a novel Fc-optimized CD40 agonistic antibody delivered intratumorally with promising efficacy in metastatic cancer patients. Among 12 participants, six experienced tumor shrinkage and two achieved complete remission, including effects on non-injected tumors, indicating a systemic immune response. This breakthrough could represent a new immunotherapeutic approach for advanced cancer, with the potential to expand treatment options where current therapies are limited.